Compare Adaptive Biotechnologies Corp (ADPT) vs Bitwise Crypto Industry Innovators ETF (BITQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Bitwise Crypto Industry Innovators ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.03 (market cap $3.33B), while Bitwise Crypto Industry Innovators ETF trades at $23.5. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Bitwise Crypto Industry Innovators ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | BITQ | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Crypto-linked |
52-Week High | $22.37 | $30.43 |
52-Week Low | $10.24 | $16.74 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BITQ trades at $24.83, up 4.37% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Support is firm near $24, while resistance sits at $25-$26. The ETF's performance remains tied to crypto industry sentiment, with recent news highlighting investor outflows from Bitcoin ETFs amid market volatility. Financial ratios are unavailable, limiting fundamental clarity.
Outlook is cautious due to bearish technicals and sector headwinds. Opportunities exist if crypto markets rebound, but risks include regulatory uncertainty and reliance on volatile underlying assets. Investors should monitor ETF inflows and broader crypto adoption trends for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →
